BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15759171)

  • 1. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
    Glynn D
    Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug prices: how they are established and existing price control systems].
    Rovira Forns J
    Salud Colect; 2015 Mar; 11(1):35-48. PubMed ID: 25853829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The aspects of pricing policy in Azerbaijan pharmaceutical sector].
    Dzhalilova KI; Alieva KIa
    Georgian Med News; 2012 Jan; (202):48-53. PubMed ID: 22392783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry.
    Thomas LG
    Pharmacoeconomics; 1994; 6 Suppl 1():67-70. PubMed ID: 10155588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.